Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.

Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C

Clinical endocrinology1 Jan 2002Cited by 87 (Europe PMC)

PMID11849248DOI10.1046/j.0300-0664.2001.01438.xPepBankPUB-11849248

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, biochemical control was 41.0% with lanreotide SR versus 37.5% with octreotide LAR, without a significant difference.
In plain wordsIn untreated acromegaly, biochemical control did not differ significantly between lanreotide and octreotide.
Peptide
Lanreotide
Outcome
No significant changeBiochemical control
Study
n = 20
Comparator
octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Biochemical control
41%
lanreotide SR (12 patients)
Biochemical control
37.5%
octreotide LAR (8 patients)
Source sentences
Summary
Biochemical control increased progressively throughout the study in patients with microadenomas more than in patients with macroadenomas (70% vs. 10%; P < 0.05) and without a difference between lanreotide SR and octreotide LAR (41.0% vs. 37.5%; P not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924801
02HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, biochemical control was 37.5% with octreotide LAR versus 41.0% with lanreotide SR, without a significant difference.
In plain wordsIn untreated acromegaly, biochemical control did not differ significantly between octreotide and lanreotide.
Peptide
Octreotide
Outcome
No significant changeBiochemical control
Study
n = 20
Comparator
lanreotide SR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Biochemical control
37.5%
octreotide LAR (8 patients)
Biochemical control
41%
lanreotide SR (12 patients)
Source sentences
Summary
Biochemical control increased progressively throughout the study in patients with microadenomas more than in patients with macroadenomas (70% vs. 10%; P < 0.05) and without a difference between lanreotide SR and octreotide LAR (41.0% vs. 37.5%; P not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924802
03HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, tumour shrinkage was 26.5 +/- 17.3% with lanreotide versus 31.1 +/- 16.1% with octreotide, without a significant difference.
In plain wordsIn untreated acromegaly, tumour shrinkage did not differ significantly between lanreotide and octreotide.
Peptide
Lanreotide
Outcome
No significant changeTumour shrinkage at 12 months
Study
n = 20
Comparator
octreotide LAR
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Tumour shrinkage (mean)
26.5%
lanreotide SR (12 patients) at 12 months
Tumour shrinkage (+/- value)
17.3%
lanreotide SR (12 patients) at 12 months
Tumour shrinkage (mean)
31.1%
octreotide LAR (8 patients) at 12 months
Tumour shrinkage (+/- value)
16.1%
octreotide LAR (8 patients) at 12 months
Source sentences
Summary
No statistical difference in the tumour shrinking effects of lanreotide SR vs. octreotide LAR was observed (26.5 +/- 17.3% vs. 31.1 +/- 16.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924803
04HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, tumour shrinkage was 31.1 +/- 16.1% with octreotide versus 26.5 +/- 17.3% with lanreotide, without a significant difference.
In plain wordsIn untreated acromegaly, tumour shrinkage did not differ significantly between octreotide and lanreotide.
Peptide
Octreotide
Outcome
No significant changeTumour shrinkage at 12 months
Study
n = 20
Comparator
lanreotide SR
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Tumour shrinkage (mean)
31.1%
octreotide LAR (8 patients) at 12 months
Tumour shrinkage (+/- value)
16.1%
octreotide LAR (8 patients) at 12 months
Tumour shrinkage (mean)
26.5%
lanreotide SR (12 patients) at 12 months
Tumour shrinkage (+/- value)
17.3%
lanreotide SR (12 patients) at 12 months
Source sentences
Summary
No statistical difference in the tumour shrinking effects of lanreotide SR vs. octreotide LAR was observed (26.5 +/- 17.3% vs. 31.1 +/- 16.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924804
05HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, tumour shrinkage was 30.0 +/- 17.2% with lanreotide versus 34.8 +/- 16.5% with octreotide, without a difference.
In plain wordsIn untreated acromegaly, tumour shrinkage at 24 months did not differ between lanreotide and octreotide.
Peptide
Lanreotide
Outcome
No significant changeTumour shrinkage at 24 months
Study
n = 20
Comparator
octreotide LAR
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Tumour shrinkage (mean)
30%
lanreotide SR (12 patients) at 24 months
Tumour shrinkage (+/- value)
17.2%
lanreotide SR (12 patients) at 24 months
Tumour shrinkage (mean)
34.8%
octreotide LAR (8 patients) at 24 months
Tumour shrinkage (+/- value)
16.5%
octreotide LAR (8 patients) at 24 months
Source sentences
Summary
At the 24th month of therapy, no further overall shrinkage was observed, compared to the 12-month evaluation (31.9 +/- 17.2% vs. 28.3 +/- 18.0%) at which there was no difference between lanreotide SR and octreotide LAR (30.0 +/- 17.2% vs. 34.8 +/- 16.5%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924805
06HumanRandomized controlled trialEfficacy outcome
In untreated acromegaly, tumour shrinkage was 34.8 +/- 16.5% with octreotide versus 30.0 +/- 17.2% with lanreotide, without a difference.
In plain wordsIn untreated acromegaly, tumour shrinkage at 24 months did not differ between octreotide and lanreotide.
Peptide
Octreotide
Outcome
No significant changeTumour shrinkage at 24 months
Study
n = 20
Comparator
lanreotide SR
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Tumour shrinkage (mean)
34.8%
octreotide LAR (8 patients) at 24 months
Tumour shrinkage (+/- value)
16.5%
octreotide LAR (8 patients) at 24 months
Tumour shrinkage (mean)
30%
lanreotide SR (12 patients) at 24 months
Tumour shrinkage (+/- value)
17.2%
lanreotide SR (12 patients) at 24 months
Source sentences
Summary
At the 24th month of therapy, no further overall shrinkage was observed, compared to the 12-month evaluation (31.9 +/- 17.2% vs. 28.3 +/- 18.0%) at which there was no difference between lanreotide SR and octreotide LAR (30.0 +/- 17.2% vs. 34.8 +/- 16.5%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned randomly to lanreotide SR (12 patients) and octreotide LAR (eight patients), and the randomization stratified patients to assure a balance between the groups with respect to baseline tumour dimension, age and sex.
Summary · context
A morphological and biochemical evaluation was performed at baseline, 12 and 24 months after beginning lanreotide SR and octreotide LAR treatment.
Report a problemFND-1184924806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.